Literature DB >> 27113402

A Benchmark for Preservation of Normal Pituitary Function After Endoscopic Transsphenoidal Surgery for Pituitary Macroadenomas.

Edward R Laws1, Sherry L Iuliano2, David J Cote2, Whitney Woodmansee3, Liangge Hsu4, Charles H Cho4.   

Abstract

INTRODUCTION: We report a contemporary consecutive series of 80 patients operated on for benign pituitary macroadenomas, followed endocrinologically for at least 3 months postoperatively. These patients were systematically evaluated preoperatively by high-resolution magnetic resonance imaging designed to detect the position of normal gland relative to the lesion. The rate of preservation of normal pituitary was critically analyzed using this strategy combined with endoscopic transsphenoidal resection.
METHODS: This is a retrospective review of 46 women and 34 men with mean postoperative follow-up of 14 months (range, 3-30 months). The lesions encountered consisted of 80 pituitary macroadenomas (55 nonfunctioning, 18 acromegaly, 5 prolactinoma, 1 Cushing, one thyroid-stimulating hormone). Pituitary endocrine status was determined preoperatively and at most recent follow-up, and categorized as normal or impaired, based on laboratory studies showing new hormone deficiency or the need for pituitary hormone replacement therapy.
RESULTS: Fifty-three patients (66.3%) had normal endocrine function preoperatively; 3 (5.7%) had loss of function postoperatively (1 transient). Twenty-seven patients (33.8%) had impaired function preoperatively; postoperatively 20 (74.1%) were unchanged, and 5 (18.5%) were worse; 2 (7.4%) recovered lost pituitary function. Of 80 patients undergoing resection, 5 (6.3%) had worsened pituitary function postoperatively. Patients with recurrent lesions (n = 5, 6.3%) and those presenting with pituitary tumor apoplexy (n = 5, 6.3%) were more likely to become further impaired. Other endocrine sequelae included 2 patients with permanent postoperative diabetes insipidus and 3 with transient symptomatic syndrome of inappropriate secretion of antidiuretic hormone.
CONCLUSIONS: The preservation and restoration of hormonal function are essential to assessing the outcome of surgery and to the patient's quality of life. Careful analysis of the anatomy of the pituitary lesions and their effect on the anatomy and physiology of the pituitary gland are crucial to success and allow modern technological advances to provide fewer complications of therapy and improved outcomes for our patients. The benchmarks provided in this article are a stimulus for even better results in the future as we take advantage of technical and conceptual advances and the benefits of multidisciplinary collaboration.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endoscopic transsphenoidal surgery; Macroadenoma; Pituitary function; Pituitary surgery

Mesh:

Year:  2016        PMID: 27113402     DOI: 10.1016/j.wneu.2016.04.059

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  11 in total

1.  Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas.

Authors:  Orsalia Alexopoulou; Valérie Everard; Martine Etoa; Edward Fomekong; Stéphane Gaillard; Fabrice Parker; Christian Raftopoulos; Philippe Chanson; Dominique Maiter
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

2.  Utility of intraoperative ultrasonography for resection of pituitary adenomas: a comparative retrospective study.

Authors:  Mohammed Alshareef; Stephen Lowe; Yeonhee Park; Bruce Frankel
Journal:  Acta Neurochir (Wien)       Date:  2021-01-05       Impact factor: 2.216

3.  The extended, transnasal, transsphenoidal approach for anterior skull base meningioma: considerations in patient selection.

Authors:  Joseph P Castlen; David J Cote; Hasan A Zaidi; Edward R Laws
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

4.  Predictors of visual and endocrine outcomes after endoscopic transsphenoidal surgery for pituitary adenomas.

Authors:  Mendel Castle-Kirszbaum; Yi Yuen Wang; James King; Tony Goldschlager
Journal:  Neurosurg Rev       Date:  2021-08-09       Impact factor: 3.042

5.  The impact of endoscopic transsphenoidal pituitary adenoma surgery on endocrine function: a single-centre study.

Authors:  Luke Galloway; Mohamed Ali; Andrew Lansdown; Peter Taylor; Aled Rees; John Stephen Davies; Caroline Hayhurst
Journal:  Acta Neurochir (Wien)       Date:  2020-10-21       Impact factor: 2.216

6.  Early hormonal recovery following endoscopic transsphenoidal surgery for silent non-functioning pituitary adenomas with hormone dysfunction.

Authors:  Min Ho Lee; Kyu Yeon Hur; Sang Duk Hong; Ho Jun Seol; Jung Won Choi; Jung- Il Lee; Do-Hyun Nam; Doo-Sik Kong
Journal:  J Neurooncol       Date:  2021-05-17       Impact factor: 4.130

7.  Multidisciplinary Team Care in the Surgical Management of Pituitary Adenoma.

Authors:  Jessica W Grayson; Agnish Nayak; Mark Winder; Benjamin Jonker; Raquel Alvarado; Henry Barham; Ann McCormack; Richard J Harvey
Journal:  J Neurol Surg B Skull Base       Date:  2019-10-21

8.  Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma.

Authors:  Lee Shwu Yi; Azmi Alias; Abdul Rahman Izaini Ghani; Mohammad Badrulnizam Long Bidin
Journal:  Malays J Med Sci       Date:  2019-06-28

9.  Transcranial approach as surgical treatment for giant pituitary adenoma during COVID 19 pandemic - What can we learn?: A case report.

Authors:  Nyoman Golden; Wayan Niryana; Steven Awyono; Putu Eka Mardhika; Made Bhuwana Putra; Made Stefanus Biondi
Journal:  Interdiscip Neurosurg       Date:  2021-02-25

10.  Post-operative volumes following endoscopic surgery for non-functioning pituitary macroadenomas are predictive of further intervention, but not endocrine outcomes.

Authors:  K Seejore; S A Alavi; S M Pearson; J M W Robins; B Alromhain; A Sheikh; P Nix; T Wilson; S M Orme; A Tyagi; N Phillips; R D Murray
Journal:  BMC Endocr Disord       Date:  2021-06-10       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.